Chimerix to Present at Virtual H.C. Wainwright Global Life Sciences Conference
March 02, 2021 07:00 ET
|
Chimerix, Inc.
DURHAM, N.C., March 02, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases,...
Chimerix Reports Promising Topline Results from First Cohort of a Randomized COVID-19 Trial with DSTAT
February 25, 2021 07:00 ET
|
Chimerix, Inc.
– Conference Call at 8:30 a.m. ET Today – DURHAM, N.C., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to...
Chimerix Reports Fourth Quarter and Year End 2020 Financial Results and Provides Operational Update
February 25, 2021 07:00 ET
|
Chimerix, Inc.
– Acquisition of Oncoceutics Adds Late-Stage Precision Oncology Pipeline – – Recently Completed Financing Supports Broad Investment Across Pipeline – – Conference Call at 8:30 a.m....
Chimerix to Report Fourth Quarter and Year End 2020 Financial Results and Provide an Operational Update on February 25, 2021
February 18, 2021 07:00 ET
|
Chimerix, Inc.
DURHAM, N.C., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases,...
Chimerix Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares
January 25, 2021 17:44 ET
|
Chimerix, Inc.
DURHAM, N.C., Jan. 25, 2021 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq: CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious...
Chimerix Announces Pricing of Public Offering of Common Stock
January 20, 2021 20:03 ET
|
Chimerix, Inc.
DURHAM, N.C., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq: CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious...
Chimerix Announces Proposed $75,000,000 Public Offering of Common Stock
January 19, 2021 16:19 ET
|
Chimerix, Inc.
DURHAM, N.C., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq: CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious...
Chimerix Acquires Oncoceutics to Expand Pipeline with Late-Stage Oncology Program
January 08, 2021 06:00 ET
|
Chimerix, Inc.
ONC201 Registrational Trial for Recurrent H3 K27M-mutant Glioma Compelling Response Rates to Date; Defined Regulatory Path to Registration Pivotal Data Anticipated in 2021 to Support Potential...
Chimerix to Present at Virtual H.C. Wainwright BioConnect 2021 Conference
January 06, 2021 08:00 ET
|
Chimerix, Inc.
DURHAM, N.C., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases,...
Chimerix Announces FDA Acceptance of New Drug Application for Brincidofovir as a Medical Countermeasure for Smallpox
December 07, 2020 07:00 ET
|
Chimerix, Inc.
DURHAM, N.C., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases,...